VacZine Analytics  
MarketVIEW - H1N1 vaccine (Global demand model)

Updated: September 2009

Pandemic influenza: Vaccine manufacturers are now actively producing H1N1 pandemic specific vaccine. The US ACIP committee has recently published recommendations regarding initial target groups for vaccination. Prioritization will be especially relevant if initial supplies are limited.

Using currently available information regarding the expected profile, predicted allocation of H1N1 specific vaccine and predictions of pandemic severity, VacZine Analytics has modelled theoretical global vaccine demand.

The provided model and presentation also give indications of potential cumulative revenue (for vaccine manufacturers) using adjustable inputs of vaccine pricing, penetration and number of doses per course.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PRICE*: PURCHASE:
VAMV007 Click here>> USD $5995.00 GBP 4199.00
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20.0%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2011 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains